Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance

European Journal of Pharmacology

Volumn 346, Issue 2-3, 1998, Pages 315-322

  Dhar, Sumeer ^a   Nygren, Peter ^a   Liminga, Gunnar ^a   Sundström, Christer ^a   De la Torre, Manuel ^b   Nilsson, Kenneth ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Calcein AM; Cytotoxic drug; Multidrug resistance; Tumor cell line

Indexed keywords

AMSACRINE; AZACITIDINE; BUSULFAN; CALCEIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORESCEIN DERIVATIVE; FLUOROURACIL; GLYCOPROTEIN P; GYRASE INHIBITOR; IDARUBICIN; MELPHALAN; NAVELBINE; TIOGUANINE; TUBULIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESPONSE; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; FLUORESCEINS; FLUORESCENT DYES; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0032502602     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00058-2     Document Type: Article

References (40)

1. Alley M., Scudiero D., Monks A., Hursey M., Czerwinski M., Fine D., Abbott B., Mayo J., Shoemaker R., Boyd M. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:1988;589-601.
2. Alvarez M., Paull K., Monks A., Hose C., Lee J., Weinstein J., Grever M., Bates S., Fojo T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute anticancer drug screen. J. Clin. Invest. 95:1995;2205-2214.
3. Anderson L.A., Esquer-Blasko R., Hofman J.P., Anderson M. A two-dimensional gel database of rat liver proteins useful in gene regulation and drug effect studies. Electrophoresis. 12:1991;907-912.
4. Azzaria M., Schurr E., Gros P. Discrete mutations introduced into the predicted nucleotide binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol. Cell. Biol. 9:1989;5289-5297.
5. Bellamy, W., Dalton, W., Gleason, M., Grogan, T., Trent, J., 1991. Development and characterisation of a melphalan-resistant human multiple myeloma cell line. Cancer Res., pp. 995-1002.
6. Botling J., Liminga G., Larsson R., Nygren P., Nilsson K. Development of vincristine resistant and increased sensitivity to cyclosporin A and verapmil in the human U-937 lymphoma cell line without overexpression of the 170 kDa P-glycoprotein. Int. J. Cancer. 58:1994;269-274.
7. Boyd, M., 1993. The future of new drug development. In: Neiderhuber, J. (Ed.), Current Therapy In Oncology. B.C. Decker, Philadelphia, pp. 11-22.
8. Boyd M.R., Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34:1995;91-109.
9. Bozyczko-Coyne D., Mckenna B.W., Connors T.J., Neff N.T. A rapid fluorometric assay to measure neuronal survival in vitro. J. Neurosci. Methods. 50:1993;205-216.
10. Cole S., Bhardwaj G., Gerlach J. Overexpression of a transport gene in a multidrug-resistance human lung cell line. Science. 258:1992;1650-1654.
11. Cordell J., Falini B., Erber W., Ghosh A., Abdulaziz Z., Macdonald S., Pulford K., Stein H., Mason D. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP Complexes). J. Histochem. Cytochem. 32:1984;219-229.
12. Dalton W., Durie B., Alberts D., Gerlach J., Cress A. Characterisation of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 46:1986;5125-5130.
13. Dalton W.S., Grogan T.M., Meltzer P.S., Scheper R.J., Durie B.G.M., Taylor C.W., Miller T.P., Salmon S.E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7:1989;415-424.
14. Danks M., Yalowich J., Beck W. Atypical multidrug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47:1987;1297-1301.
15. Danks M., Schmidt C., Cirtain M., Suttle D., Beck W.T. Altered catalytic activity of and DNA cleavage by DNA topoisomeras II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
16. Dhar S., Nygren P., Csoka K., Botling J., Nilsson K., Larsson R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Br. J. Cancer. 74:1996;888-896.
17. Feller N., Broxterman H., Wahrer D., Pinedo H. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 386:1995;385-388.
18. Feller N., Kuiper C., Lankelma J., Ruhdal J., Scheper R., Pinedo H., Broxterman H. Functional detection of MDR1/P190-mediated multidrug resistance in tumor cells by flow cytometry. Br. J. Cancer. 72:1995;543-549.
19. Grant C., Valdimarsson G., Hipfner D., Almquist K., Cole S., Deeley R. Overexpression of multidrug resistance-associated protein (MRP) increases to natural product drugs. Cancer Res. 54:1994;357-361.
20. Hollo Z. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta. 384:1994;1191-1198.
21. Hollo Z., Homolya L., Hegedus T., Sarkadi B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumor cells. FEBS Lett. 383:1996;99-104.
22. Larsson R., Nygren P. A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res. 9:1989;1111-1120.
23. Larsson R., Nygren P. Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int. J. Cancer. 46:1990;67-72.
24. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer. 50:1992;177-185.
25. Lee J., Paull K., Alvarez M., Hose C., Monks M., Grever M., Fojo A., Bates S. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46:1994;627-638.
26. Liang P., Pardee A.B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science. 257:1992;967-971.
27. Liminga G., Nygren P., Larsson R. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effect of cyclosporin A and its non-immunosuppressive analogue SDZ PSC 833. Exp. Cell Res. 212:1994;291-296.
28. Mirski S., Gerlach J., Cole S.P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47:1987;2594-2598.
29. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-765.
30. Morris S. Real-time multi-wavelength fluorescence imaging of living cells. BioTechniques. 8:1990;296-312.
31. Mulcahy R., Bailey H., Gipp J. Up-regulation of gamma-glutamylcyateine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother. Pharmacol. 34:1994;67-71.
32. Myers T.G., Anderson N.L., Waltham M., Li G., Buolamwini J.K., Scudiero D.A., Paull K.D., Sausville E.A., Weinstein J.N. A protein expression database for the molecular pharmacology of cancer. Electrophoresis. 18:1997;1-7.
33. Nygren P., Larsson R. Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators. Int. J. Cancer. 48:1991;598-604.
34. Paull K., Shoemaker R., Hodes L., Monks A., Scudiero D., Rubinstein L., Plowman J., Boyd M. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81:1989;1088-1092.
35. Slovak M., Ho J., Bhardwaj G., Kurz E., Deeley R., Cole S. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 53:1993;3221-3225.
36. Tsuruo T., Tomida T. Multidrug resistance. Anticancer Drugs. 6:1995;213-218.
37. Versantvoort C., Bagrij T., Wright K., Twentyman P. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int. J. Cancer. 63:1995;855-862.
38. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J. Jr., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., Van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. An information-intensive approach to the molecular pharmacology of cancer. Science. 275:1997;343-349.
39. Weston S., Parish C. New fluorescent dyes for lymphocyte migration studies. J. Immunol. Methods. 133:1990;87-97.
40. Wu L., Symthe A.M., Stinson S.F., Mullendore L.A., Monks A., Scudiero D.A., Paull K.D., Koutsoukos A.D., Rubinstein L.V., Boyd M.R., Shoemaker R.H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res. 52:1992;3029-3034.